UPC Analytics
DEEN
Übersicht · Eingereicht: 6. Juni 2023

UPC_CFI_75/2023

METHOD OF PRODUCING RETINAL PIGMENT EPITHELIAL CELL

NichtigkeitHauptnichtigkeitsklageMunich CDRevocationCase ClosedVergleich erfolgt: Vor Hauptsache
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Parteien

Kläger

  • ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Vertreter: Mark Didmon (Potter Clarkson)

Beklagte

  • Healios K.K
  • Riken
  • Osaka University
Vertreter: James Nicholls (JA Kemp); Pamela Tuxworth (JA Kemp)
Richter
  • Ulrike Voß
  • Andras Kupecz
  • Paolo Gerli
Patente
  • EP3056563
  • EP 3 056 563
  • EP 3 056 564
CPC-Codes: A61P27/02, C12N2501/727, C12N2506/45, C12N2533/52, A61K9/0048, A61K35/30, C12N2509/00, C12N5/0621

Technologiebereich: Biotech · Cell Therapy

Sektor: Biotechnology

Ausgang
VergleichVergleich
Eingereicht: 6. Juni 2023
Erste Entscheidung: 21. Sept. 2023
Letzte Entscheidung: 18. März 2024
Sprache: English
Vergleich erfolgt: Vor Hauptsache — settled commercially

Order from the Munich Central Division (Section) dated 23 July 2024 disposing of two revocation actions brought by Astellas Institute for Regenerative Medicine against Healios K.K., Riken and Osaka University. Both parties submitted a unanimous application under R. 360 RoP declaring that they concluded the actions by settlement and that the actions were devoid of purpose. The court held that parties may settle without seeking a confirmatory court decision under R. 365 RoP and declared the proceedings closed. A 20% reimbursement of court fees was granted under R. 370.9(c) RoP. Headnotes clarify that settlement-based closures are not limited to the formal R. 365 confirmation procedure.

Im UPC-Register öffnen